Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
4
100%

Phase Distribution

0

Early Stage

4

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 2Efficacy & side effects
4(100.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(1)
Other(3)

Detailed Status

unknown3
Completed1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 24 (100.0%)

Trials by Status

completed125%
unknown375%

Recent Activity

0 active trials
Showing 4 of 4
unknownphase_2

Autologous Immune Killer Cells to Treat Liver Cancer Patients as an Adjunct Therapy

NCT03592706
completedphase_2

Combination of Transcatheter Arterial Chemoembolization (TACE) and Sorafenib for Patients With Unresectable Hepatocellular Carcinoma (HCC)

NCT00919009
unknownphase_2

Trial of Transcatheter Arterial Chemoembolization (TACE) With Sorafenib for Locally Advanced Hepatocellular Carcinoma (HCC)

NCT01170104
unknownphase_2

Study in Asia of the Combination of TACE With Sorafenib in HCC Patients

NCT00990860

Clinical Trials (4)

Showing 4 of 4 trials
NCT03592706Phase 2

Autologous Immune Killer Cells to Treat Liver Cancer Patients as an Adjunct Therapy

Unknown
NCT00919009Phase 2

Combination of Transcatheter Arterial Chemoembolization (TACE) and Sorafenib for Patients With Unresectable Hepatocellular Carcinoma (HCC)

Completed
NCT01170104Phase 2

Trial of Transcatheter Arterial Chemoembolization (TACE) With Sorafenib for Locally Advanced Hepatocellular Carcinoma (HCC)

Unknown
NCT00990860Phase 2

Study in Asia of the Combination of TACE With Sorafenib in HCC Patients

Unknown

All 4 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
4